Skip to main content

Table 2 Time on treatment from LOT1 initiation, abatacept compared to other bDMARD therapy

From: Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study

bDMARD therapy Median (months) R-Mean (months) Max Follow Up (months) Month 12 (%) Month 24 (%) Month 36 (%) P-value
Abatacept 53.4 41.2 53.4 85.6% 70.9% 70.9% W:< 0.01*
LR:< 0.01*
Other 17.4 31.4 139.9 63.4% 39.3% 31.7%
  1. bDMARD Biologic disease-modifying antirheumatic drug, LOT Line of therapy, LR Log-Rank, R-Mean Restricted-mean (mean survival restricted at maximum follow-up within the cohort), W Wilcoxon
  2. * Denotes significance at p-value < 0.05